Head and Neck Cancer – the Rationale behind Different Therapeutic Approaches

Dear Colleagues,

Decisions aiming for the best treatment of head and neck cancer (HNC) patients have to be made during everyday clinical practice. These therapeutic decisions are typically tailored to the specific situation of the single HNC patient. Therapy choice is highly dependent on the patient’s tumor stage but also has to consider other factors such as the patient’s age and morbidity. To offer a patient the best possible therapy option, interdisciplinary decision making is required, involving disciplines such as otorhinolaryngology and head and neck surgery, oral and maxillofacial surgery, radiation oncology, pathology, and internal medicine. Over the past years, new disciplines, such as molecular pathology, as the basis for precision medicine, are becoming more and more prevalent owing to the fact that gaining information about tumor genomes can have a major impact on therapeutic choices particularly in patients which have no other treatment options. To address this complex situation, this Special Issue focuses on aspects that influence the choice of therapy for HNC patients. For this, it is of utmost importance to bring together opinions and expertise from clinically and basic-research focused disciplines.

We therefore would like to invite and encourage you to contribute an article (original or review) to your area of expertise in the field of HNC and discuss how you think this could impact HNC therapeutic decision making.

With kind regards,

Prof. Dr. Robert Mandic
Prof. Dr. Boris A. Stuck
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.